Tremfya is not a biosimilar; it is a biologic drug. Biosimilars are approved versions of already approved biologic medicines that are highly similar to the reference product. Tremfya is a specific biologic therapy.
What is Tremfya?
Tremfya, with the active ingredient guselkumab, is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1]. It is also approved for adults with active psoriatic arthritis [1]. Tremfya works by targeting a protein called interleukin-23 (IL-23), which plays a role in inflammatory diseases [1].
How are Biologics Different from Biosimilars?
Biologics are complex medicines derived from living organisms. Biosimilars are highly similar versions of these reference biologics, demonstrating no clinically meaningful differences in terms of safety, purity, and potency [2]. The development and approval process for biosimilars aims to ensure they are comparable to the reference product, allowing for potential cost savings and increased treatment options [2].
When Does Tremfya's Patent Exclusivity Expire?
Information regarding the specific patent expiration dates for Tremfya can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed information on patent statuses and expiry timelines for various medications [3].
Who Makes Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
Can Generic Versions of Tremfya Be Developed?
Biologic drugs like Tremfya cannot have generic versions in the same way that small-molecule drugs do. Instead, the equivalent of generics for biologics are biosimilars [2].
What Other Treatments Exist for Plaque Psoriasis and Psoriatic Arthritis?
Treatment options for plaque psoriasis and psoriatic arthritis vary depending on the severity of the condition and individual patient needs. These can include topical treatments, phototherapy, oral medications, and other injectable biologic therapies that target different inflammatory pathways [1].